VistaGen Therapeutics Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Shawn Singh (59 yo)
23.08yrs
Tenure
US$1,182,460
Compensation
Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....
CEO Compensation Analysis
| Date | Total Comp. | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$60m |
| Mar 31 2022 | US$1m | US$563k | -US$49m |
| Dec 31 2021 | n/a | n/a | -US$62m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | US$1m | US$511k | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | US$934k | US$498k | -US$22m |
| Dec 31 2019 | n/a | n/a | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | US$951k | US$466k | -US$26m |
| Dec 31 2018 | n/a | n/a | -US$24m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | US$1m | US$425k | -US$16m |
| Dec 31 2017 | n/a | n/a | -US$14m |
| Sep 30 2017 | n/a | n/a | -US$13m |
| Jun 30 2017 | n/a | n/a | -US$12m |
| Mar 31 2017 | US$1m | US$385k | -US$12m |
| Dec 31 2016 | n/a | n/a | -US$18m |
| Sep 30 2016 | n/a | n/a | -US$19m |
| Jun 30 2016 | n/a | n/a | -US$24m |
| Mar 31 2016 | US$2m | US$348k | -US$51m |
Compensation vs Market: Shawn's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD724.43K).
Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.5yrs | US$1.18m | 0.38% $ 235.6k | |
| Chief Financial Officer | 11.42yrs | US$712.11k | 0.051% $ 31.5k | |
| Chief Corporate Development & Legal Officer | 0.75yr | no data | 0.16% $ 100.4k | |
| Senior Vice President of Business Operations | 0.25yr | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Development Operations | no data | no data | no data | |
| Senior VP and Head of Chemistry | 2yrs | no data | no data | |
| Senior Vice President of Medical Research & Pharmacovigilance | no data | no data | no data | |
| VP, Associate General Counsel & Corporate Secretary | 0.50yr | no data | no data |
1.4yrs
Average Tenure
63.5yo
Average Age
Experienced Management: VTGN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 23.08yrs | US$1.18m | 0.38% $ 235.6k | |
| Independent Chairman | 23.08yrs | US$160.64k | 0.027% $ 16.7k | |
| Independent Director | 6.92yrs | US$160.95k | 0.19% $ 120.0k | |
| Chairman of Scientific Advisory Board | 0.17yr | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 6.92yrs | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 7.33yrs | no data | no data | |
| Member of CNS Clinical and Regulatory Advisory Board | 4.33yrs | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 5.58yrs | no data | no data | |
| Member of Clinical & Regulatory Advisory Board | 8yrs | no data | no data | |
| Independent Director | 1.58yrs | US$305.50k | 0% $ 0 | |
| Director | 1.08yrs | US$1.25m | 0% $ 0 | |
| Member of Clinical & Regulatory Advisory Board | 6.92yrs | no data | no data |
6.9yrs
Average Tenure
62yo
Average Age
Experienced Board: VTGN's board of directors are considered experienced (6.9 years average tenure).